Skip to main content
Top
Published in: International Urology and Nephrology 6/2019

Open Access 01-06-2019 | Malnutrition | Nephrology - Original Paper

Hypomagnesemia is not an independent risk factor for mortality in Japanese maintenance hemodialysis patients

Authors: Sonoo Mizuiri, Yoshiko Nishizawa, Kazuomi Yamashita, Takayuki Naito, Kyoka Ono, Chie Tanji, Koji Usui, Shigehiro Doi, Takao Masaki, Kenichiro Shigemoto

Published in: International Urology and Nephrology | Issue 6/2019

Login to get access

Abstract

Purpose

It is unclear whether hypomagnesemia is an independent risk factor or innocent bystander for mortality in maintenance hemodialysis (MHD) patients. Thus, we studied associations between hypomagnesemia and all-cause as well as cardiovascular (CV) mortality in MHD patients.

Methods

Baseline clinical characteristics and coronary artery calcium score (CACS) of 353 Japanese MHD patients were reviewed. Three-year survival rate and mortality risk factors were assessed.

Results

Median (interquartile range) age, dialysis vintage, serum magnesium (Mg), serum albumin and CACS of the subjects were 68 (60–78) years, 75 (32–151) months, 2.4 (2.2–2.7) mg/dl, 3.6 (3.3–3.8) g/dl, and 1181 (278–3190), respectively. During the 3-year period, 91 patients died. Kaplan–Meier overall 3-year survival rates were 59.0% in in patients with Mg < 2.4 mg/dl (n = 136) and 82.3% in patients with Mg ≥ 2.4 mg/dl (n = 217), (P < 0.0001). In Cox regression models not incorporating serum albumin, Mg < 2.4 mg/dl was significantly associated with 3-year all-cause death, independent of age, dialysis vintage, average ultrafiltration, Log (CACS + 1), warfarin use, serum potassium, high-sensitivity C-reactive protein (hsCRP), phosphate, uric acid, and intact parathyroid hormone [Hazard ratio (HR) 95% confidence interval (CI): 2.82 (1.31–6.29), P = 0.0078], and CV death, independent of age, dialysis vintage, Log (CACS + 1), warfarin use, serum hsCRP, and uric acid [HR (95% CI): 4.47 (1.45–16.76), P = 0.0086]. Nevertheless, associations of Mg < 2.4 mg/dl with all-cause and CV mortality were all absent in models that included serum albumin.

Conclusions

Hypomagnesemia is not an independent risk factor for mortality but is associated with malnutrition in MHD patients.
Literature
1.
go back to reference Hamano N, Komaba H, Fukagawa M (2017) Magnesium as a new player in CKD: too little is as bad as too much? Kidney Int 92:1034–1036CrossRefPubMed Hamano N, Komaba H, Fukagawa M (2017) Magnesium as a new player in CKD: too little is as bad as too much? Kidney Int 92:1034–1036CrossRefPubMed
2.
go back to reference Sakaguchi Y, Hamano T, Isaka Y (2018) Magnesium in hemodialysis patients: a new understanding of the old problem. Contrib Nephrol 196:58–63CrossRefPubMed Sakaguchi Y, Hamano T, Isaka Y (2018) Magnesium in hemodialysis patients: a new understanding of the old problem. Contrib Nephrol 196:58–63CrossRefPubMed
3.
go back to reference Alhosaini M, Leehey DJ (2015) Magnesium and dialysis: the neglected cation. Am J Kidney Dis 66:523–531CrossRefPubMed Alhosaini M, Leehey DJ (2015) Magnesium and dialysis: the neglected cation. Am J Kidney Dis 66:523–531CrossRefPubMed
4.
go back to reference Misra PS, Nessim SJ (2017) Clinical aspects of magnesium physiology in patients on dialysis. Semin Dial 30:438–445CrossRefPubMed Misra PS, Nessim SJ (2017) Clinical aspects of magnesium physiology in patients on dialysis. Semin Dial 30:438–445CrossRefPubMed
5.
go back to reference Montezano AC, Zimmerman D, Yusuf H, Burger D, Chignalia AZ, Wadhera V, van Leeuwen FN, Touyz RM (2010) Vascular smooth muscle cell differentiation to an osteogenic phenotype involves TRPM7 modulation by magnesium. Hypertension 56:453–462CrossRefPubMed Montezano AC, Zimmerman D, Yusuf H, Burger D, Chignalia AZ, Wadhera V, van Leeuwen FN, Touyz RM (2010) Vascular smooth muscle cell differentiation to an osteogenic phenotype involves TRPM7 modulation by magnesium. Hypertension 56:453–462CrossRefPubMed
6.
go back to reference Pasch A, Farese S, Gräber S, Wald J, Richtering W, Floege J, Jahnen-Dechent W (2012) Nanoparticle-based test measures overall propensity for calcification in serum. J Am Soc Nephrol 23:1744–1752CrossRefPubMedPubMedCentral Pasch A, Farese S, Gräber S, Wald J, Richtering W, Floege J, Jahnen-Dechent W (2012) Nanoparticle-based test measures overall propensity for calcification in serum. J Am Soc Nephrol 23:1744–1752CrossRefPubMedPubMedCentral
7.
go back to reference Diaz-Tocados JM, Peralta-Ramirez A, Rodríguez-Ortiz ME et al (2017) Dietary magnesium supplementation prevents and reverses vascular and soft tissue calcifications in uremic rats. Kidney Int 92:1084–1099CrossRefPubMed Diaz-Tocados JM, Peralta-Ramirez A, Rodríguez-Ortiz ME et al (2017) Dietary magnesium supplementation prevents and reverses vascular and soft tissue calcifications in uremic rats. Kidney Int 92:1084–1099CrossRefPubMed
8.
go back to reference Sakaguchi Y, Fujii N, Shoji T, Hayashi T, Rakugi H, Isaka Y (2014) Hypomagnesemia is a significant predictor of cardiovascular and non-cardiovascular mortality in patients undergoing hemodialysis. Kidney Int 85:174–181CrossRefPubMed Sakaguchi Y, Fujii N, Shoji T, Hayashi T, Rakugi H, Isaka Y (2014) Hypomagnesemia is a significant predictor of cardiovascular and non-cardiovascular mortality in patients undergoing hemodialysis. Kidney Int 85:174–181CrossRefPubMed
9.
go back to reference Lacson E Jr, Wang W, Ma L, Passlick-Deetjen J (2015) Serum magnesium and mortality in hemodialysis patients in the United States: a cohort study. Am J Kidney Dis 66:1056–1066CrossRefPubMed Lacson E Jr, Wang W, Ma L, Passlick-Deetjen J (2015) Serum magnesium and mortality in hemodialysis patients in the United States: a cohort study. Am J Kidney Dis 66:1056–1066CrossRefPubMed
10.
go back to reference Schmaderer C, Braunisch MC, Suttmann Y, Lorenz G, Pham D, Haller B, Angermann S, Matschkal J, Renders L, Baumann M, Braun JR, Heemann U, Küchle C (2017) Reduced mortality in maintenance haemodialysis patients on high versus low dialysate magnesium. A pilot study. Nutrients 9:E926CrossRefPubMed Schmaderer C, Braunisch MC, Suttmann Y, Lorenz G, Pham D, Haller B, Angermann S, Matschkal J, Renders L, Baumann M, Braun JR, Heemann U, Küchle C (2017) Reduced mortality in maintenance haemodialysis patients on high versus low dialysate magnesium. A pilot study. Nutrients 9:E926CrossRefPubMed
11.
go back to reference Courivaud C, Davenport A (2014) Magnesium and the risk of all-cause and cardiac mortality in hemodialysis patients: agent provocateur or innocent bystander? Kidney Int 85:17–20CrossRefPubMed Courivaud C, Davenport A (2014) Magnesium and the risk of all-cause and cardiac mortality in hemodialysis patients: agent provocateur or innocent bystander? Kidney Int 85:17–20CrossRefPubMed
12.
go back to reference Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R (1990) Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 15:827–832CrossRefPubMed Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R (1990) Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 15:827–832CrossRefPubMed
13.
go back to reference João Matias P, Azevedo A, Laranjinha I, Navarro D, Mendes M, Ferreira C, Amaral T, Jorge C, Aires I, Gil C, Ferreira A (2014) Lower serum magnesium is associated with cardiovascular risk factors and mortality in haemodialysis patients. Blood Purif 38:244–252CrossRefPubMed João Matias P, Azevedo A, Laranjinha I, Navarro D, Mendes M, Ferreira C, Amaral T, Jorge C, Aires I, Gil C, Ferreira A (2014) Lower serum magnesium is associated with cardiovascular risk factors and mortality in haemodialysis patients. Blood Purif 38:244–252CrossRefPubMed
14.
go back to reference de Roij van Zuijdewijn CL, Grooteman MP, Bots ML, Blankestijn PJ, Steppan S, Büchel J, Groenwold RH, Brandenburg V, van den Dorpel MA, Ter Wee PM, Nubé MJ, Vervloet MG (2015) Serum magnesium and sudden death in European hemodialysis patients. PLoS ONE 10:e0143104CrossRef de Roij van Zuijdewijn CL, Grooteman MP, Bots ML, Blankestijn PJ, Steppan S, Büchel J, Groenwold RH, Brandenburg V, van den Dorpel MA, Ter Wee PM, Nubé MJ, Vervloet MG (2015) Serum magnesium and sudden death in European hemodialysis patients. PLoS ONE 10:e0143104CrossRef
15.
go back to reference Selim GN, Spasovski G, Tozija L, Georgievska-Ismail L, Zafirova-Ivanovska B, Masin-Spasovska J, Rambabova-Busletic I, Petronijevic Z, Dzekova-Vidimliski P, Ristovska V, Pusevski V, Stojceva-Taneva O (2017) Hypomagnesemia and cause-specific mortality in hemodialysis patients: 5-year follow-up analysis. Int J Artif Organs 40:542–549CrossRefPubMed Selim GN, Spasovski G, Tozija L, Georgievska-Ismail L, Zafirova-Ivanovska B, Masin-Spasovska J, Rambabova-Busletic I, Petronijevic Z, Dzekova-Vidimliski P, Ristovska V, Pusevski V, Stojceva-Taneva O (2017) Hypomagnesemia and cause-specific mortality in hemodialysis patients: 5-year follow-up analysis. Int J Artif Organs 40:542–549CrossRefPubMed
16.
go back to reference Ishimura E, Okuno S, Kitatani K, Tsuchida T, Yamakawa T, Shioi A, Inaba M, Nishizawa Y (2007) Significant association between the presence of peripheral vascular calcification and lower serum magnesium in hemodialysis patients. Clin Nephrol 68:222–227CrossRefPubMed Ishimura E, Okuno S, Kitatani K, Tsuchida T, Yamakawa T, Shioi A, Inaba M, Nishizawa Y (2007) Significant association between the presence of peripheral vascular calcification and lower serum magnesium in hemodialysis patients. Clin Nephrol 68:222–227CrossRefPubMed
17.
go back to reference Masakane I, Nakai S, Ogata S, Kimata N, Hanafusa N, Hamano T, Wakai K, Wada A, Nitta K (2015) An overview of regular dialysis treatment in Japan (As of 31 December 2013). Ther Apher Dial 19:540–574CrossRefPubMed Masakane I, Nakai S, Ogata S, Kimata N, Hanafusa N, Hamano T, Wakai K, Wada A, Nitta K (2015) An overview of regular dialysis treatment in Japan (As of 31 December 2013). Ther Apher Dial 19:540–574CrossRefPubMed
18.
go back to reference Navarro-González JF (1998) Magnesium in dialysis patients: serum levels and clinical implications. Clin Nephrol 49:373–378PubMed Navarro-González JF (1998) Magnesium in dialysis patients: serum levels and clinical implications. Clin Nephrol 49:373–378PubMed
19.
go back to reference Gonella M, Ballanti P, Della Rocca C, Calabrese G, Pratesi G, Vagelli G, Mazzotta A, Bonucci E (1988) Improved bone morphology by normalizing serum magnesium in chronically hemodialyzed patients. Miner Electrolyte Metab 14:240–245PubMed Gonella M, Ballanti P, Della Rocca C, Calabrese G, Pratesi G, Vagelli G, Mazzotta A, Bonucci E (1988) Improved bone morphology by normalizing serum magnesium in chronically hemodialyzed patients. Miner Electrolyte Metab 14:240–245PubMed
20.
go back to reference Liu F, Zhang X, Qi H, Wang J, Wang M, Zhang Y, Yan H, Zhuang S (2013) Correlation of serum magnesium with cardiovascular risk factors in maintenance hemodialysis patients-a cross-sectional study. Magnes Res 26:100–108PubMed Liu F, Zhang X, Qi H, Wang J, Wang M, Zhang Y, Yan H, Zhuang S (2013) Correlation of serum magnesium with cardiovascular risk factors in maintenance hemodialysis patients-a cross-sectional study. Magnes Res 26:100–108PubMed
21.
go back to reference Fein P, Suda V, Borawsky C, Kapupara H, Butikis A, Matza B, Chattopadhyay J, Avra MM (2010) Relationship of serum magnesium to body composition and inflammation in peritoneal dialysis patients. Adv Perit Dial 26:112–115PubMed Fein P, Suda V, Borawsky C, Kapupara H, Butikis A, Matza B, Chattopadhyay J, Avra MM (2010) Relationship of serum magnesium to body composition and inflammation in peritoneal dialysis patients. Adv Perit Dial 26:112–115PubMed
22.
go back to reference Li L, Streja E, Rhee CM, Mehrotra R, Soohoo M, Brunelli SM, Kovesdy CP, Kalantar-Zadeh K (2015) Hypomagnesemia and mortality in incident hemodialysis patients. Am J Kidney Dis 66:1047–1055CrossRefPubMedPubMedCentral Li L, Streja E, Rhee CM, Mehrotra R, Soohoo M, Brunelli SM, Kovesdy CP, Kalantar-Zadeh K (2015) Hypomagnesemia and mortality in incident hemodialysis patients. Am J Kidney Dis 66:1047–1055CrossRefPubMedPubMedCentral
23.
go back to reference Browne OT, Allgar V, Bhandari S (2014) Analysis of factors predicting mortality of new patients commencing renal replacement therapy 10 years of follow-up. BMC Nephrol 15:20CrossRefPubMedPubMedCentral Browne OT, Allgar V, Bhandari S (2014) Analysis of factors predicting mortality of new patients commencing renal replacement therapy 10 years of follow-up. BMC Nephrol 15:20CrossRefPubMedPubMedCentral
24.
go back to reference Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Jüppner H, Wolf M (2008) Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359:584–592CrossRefPubMedPubMedCentral Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Jüppner H, Wolf M (2008) Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359:584–592CrossRefPubMedPubMedCentral
25.
go back to reference Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C (2009) High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 24:2792–2796CrossRefPubMed Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C (2009) High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 24:2792–2796CrossRefPubMed
26.
go back to reference Olauson H, Qureshi AR, Miyamoto T, Barany P, Heimburger O, Lindholm B, Stenvinkel P, Larsson TE (2010) Relation between serum fibroblast growth factor-23 level and mortality in incident dialysis patients: are gender and cardiovascular disease confounding the relationship? Nephrol Dial Transplant 25:3033–3038CrossRefPubMed Olauson H, Qureshi AR, Miyamoto T, Barany P, Heimburger O, Lindholm B, Stenvinkel P, Larsson TE (2010) Relation between serum fibroblast growth factor-23 level and mortality in incident dialysis patients: are gender and cardiovascular disease confounding the relationship? Nephrol Dial Transplant 25:3033–3038CrossRefPubMed
27.
go back to reference Kojima F, Uchida K, Ogawa T, Tanaka Y, Nitta K (2008) Plasma levels of fibroblast growth factor-23 and mineral metabolism in diabetic and non-diabetic patients on chronic hemodialysis. Int Urol Nephrol 40:1067–1074CrossRefPubMed Kojima F, Uchida K, Ogawa T, Tanaka Y, Nitta K (2008) Plasma levels of fibroblast growth factor-23 and mineral metabolism in diabetic and non-diabetic patients on chronic hemodialysis. Int Urol Nephrol 40:1067–1074CrossRefPubMed
28.
go back to reference Shemin D, Bostom AG, Laliberty P, Dworkin LD (2001) Residual renal function and mortality risk in hemodialysis patients. Am J Kidney Dis 38:85–90CrossRefPubMed Shemin D, Bostom AG, Laliberty P, Dworkin LD (2001) Residual renal function and mortality risk in hemodialysis patients. Am J Kidney Dis 38:85–90CrossRefPubMed
29.
go back to reference Lee MJ, Park JT, Park KS, Kwon YE, Oh HJ, Yoo TH, Han SH, Kim YL, Kim YS, Yang CW, Kim NH, Kang SW (2017) Prognostic value of residual urine volume, GFR by 24-hour urine collection, and eGFR in patients receiving dialysis. Clin J Am Soc Nephrol 12:426–443CrossRefPubMedPubMedCentral Lee MJ, Park JT, Park KS, Kwon YE, Oh HJ, Yoo TH, Han SH, Kim YL, Kim YS, Yang CW, Kim NH, Kang SW (2017) Prognostic value of residual urine volume, GFR by 24-hour urine collection, and eGFR in patients receiving dialysis. Clin J Am Soc Nephrol 12:426–443CrossRefPubMedPubMedCentral
Metadata
Title
Hypomagnesemia is not an independent risk factor for mortality in Japanese maintenance hemodialysis patients
Authors
Sonoo Mizuiri
Yoshiko Nishizawa
Kazuomi Yamashita
Takayuki Naito
Kyoka Ono
Chie Tanji
Koji Usui
Shigehiro Doi
Takao Masaki
Kenichiro Shigemoto
Publication date
01-06-2019
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 6/2019
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-019-02073-w

Other articles of this Issue 6/2019

International Urology and Nephrology 6/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.